Navigation Links
Caraco Pharmaceutical Laboratories, Ltd. Announces Tentative FDA Approval for Generic Lamictal(R)
Date:11/12/2007

DETROIT, Nov. 12 /PRNewswire-FirstCall/ -- Caraco Pharmaceutical Laboratories, Ltd., (Amex: CPD) announced today that the US Food and Drug Administration (FDA) has granted tentative approval for the Company's Abbreviated New Drug Application (ANDA) for Lamotrigine Tablets (lamotrigine), 25 mg, 100 mg, 150 mg, and 200 mg. Final approval to market this product is anticipated subsequent to the expiry of patent protection on January 22, 2009.

Lamotrigine is indicated as adjunctive therapy for partial seizures (the generalized seizures of Lennox-Gastaut syndrome), is indicated for conversion to monotherapy in adults with partial seizures who are receiving treatment with carbamazepine, phenytoin, phenobarbital, primidone, or valproate as the single AED, and is indicated for the maintenance treatment of Bipolar I Disorder to delay the time to occurrence of mood episodes (depression, mania, hypomania, mixed episodes) in patients treated for acute mood episodes with standard therapy.

This tentative approval is the bioequivalent to Lamictal(R), a registered trademark of GlaxoSmithKline. Lamictal(R) tablets had U.S. sales of approximately $1.89 billion for the 12-month period ended September 30, 2007, according to IMS Data.

Daniel H. Movens, Caraco's Chief Executive Officer, said, "We are extremely pleased to receive this tentative approval and look forward to the expiration date of the patent in January 2009, which will allow Caraco to market the product. We feel that generic Lamictal(R) will be a positive addition to our portfolio by expanding our product offerings."

Detroit-based Caraco Pharmaceutical Laboratories, Ltd., develops, manufactures, markets and distributes generic and private-label pharmaceu
'/>"/>

SOURCE Caraco Pharmaceutical Laboratories, Ltd.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
2. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
3. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Coreg(R)
4. Caraco Pharmaceutical Laboratories Ltd. Announces Tentative FDA Approval for Generic Zyrtec Chewable(R)
5. Caraco Pharmaceutical Laboratories Ltd. Reports Record Net Sales for the Second Quarter and First Six Months of Fiscal 2008
6. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
7. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
8. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
9. National Pharmaceutical Council Announces New Strategic Focus, Search for New Leadership
10. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
11. Par Pharmaceutical Files Form 10-K for 2006 -- Company to Hold First Analysts Meeting September 28, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/28/2015)... My Shiney Hiney® LLC., the renowned brand ... Las Vegas, Nevada for the annual ASD Market Week tradeshow. ... leading consumer-goods tradeshows and My Shiney Hiney will be one ... Shiney Hiney can be found at booth number C1663. , ... at-home personal hygiene brush and cleansing system exclusively created to ...
(Date:2/27/2015)... 27, 2015 OnChip Devices , ... introduced miniature, wire bondable, silicon ESD (Electrostatic Discharge) protection ... The ESD88NP and ESD88PN ... sensitive LED and IC products. These Zeners exhibit ... All devices meet the requirements of IEC61000 and ...
(Date:2/27/2015)... 2015 Today, February 27th, is "Shine A ... along with LXR Organics and Living Fuel, ... to raise awareness and promote prevention, rescue and restoration for ... the END IT Coalition, slavery is the 2nd largest global ... in 167 countries around the world. Slavery includes bonded labor, ...
(Date:2/27/2015)... Altec Products, Inc., announced today that ADSS ... Management Partner of the Year. ADSS Global provides Sage ... complimentary solutions for their customers across the world. Altec ... to provide clients with paperless solutions that integrate seamlessly ... thrilled to recognize ADSS Global for their expertise in ...
(Date:2/27/2015)... Calif. (PRWEB) February 27, 2015 ... who are documented to use Medicaid, the federal ... families, according to a new study from UC ... the greatest predictor of farmworker use of Medicaid, ... care regardless of documentation status, was having children. ...
Breaking Medicine News(10 mins):Health News:My Shiney Hiney® to Participate in ASD Market Week 2015 2Health News:OnChip Introduces New Series of Space Saving Bare-die Zener Diodes for Transient Voltage Suppression 2Health News:OnChip Introduces New Series of Space Saving Bare-die Zener Diodes for Transient Voltage Suppression 3Health News:KAJ Brothers Join the Campaign to 'End It - Shine A Light On Slavery' 2Health News:Altec Announces 2014 Sage ERP Document Management Partner of the Year Award Recipient 2Health News:UC Davis Study Finds Undocumented Farmworkers Use Medicaid Half as Often as Documented Farmworkers 2Health News:UC Davis Study Finds Undocumented Farmworkers Use Medicaid Half as Often as Documented Farmworkers 3
... Discusses key issues ... ... only on motivating employees, but also on how supportive companies are of the program, according ... High-Engagement Wellness Program , scheduled for Thursday, April 22 at 3:00 pm EST, Fiona Gathright, ...
... Medication offers hope for treatment with fewer side effects, experts ... reporting that a drug is showing promise in early testing ... and potentially deadly liver ailment. , It,s too early to ... years before it,s ready to seek federal approval to be ...
... discovery 15 years ago that the genes BRCA1 and ... was a breakthrough for cancer prediction and therapy, especially ... Alfons Meindl (Klinikum rechts der Isar of the Technische ... the U.K., and the U.S., can identify another gene ...
... Dr. ... of skin care products that claim to be "natural" or "organic" have cancer-causing ingredients. ... New York, NY (PRWEB) April ... recent study: a number of skin care products that claim to be "natural" or "organic" ...
... ... that allows unlimited penetration testing against your environment to help achieve compliance, such as ... , ... 21, 2010 -- Clone Systems, Inc. has introduced Clone Guard® CG-PenTest, a web portal ...
... D.C. (April 21, 2010)Past randomized clinical trials have ... can reduce the risk of colon cancer and ... Chase Cancer Center have found that an investigational ... can block one of the earliest molecular changes ...
Cached Medicine News:Health News:DSM Personalized Nutrition Webinar Examines Ways to Build Engagement in Wellness Programs 2Health News:DSM Personalized Nutrition Webinar Examines Ways to Build Engagement in Wellness Programs 3Health News:In Early Test, New Hepatitis C Drug Shows Promise 2Health News:Researchers identify a new breast and ovarian cancer susceptibility gene 2Health News:Carcinogen Found in Many "Natural" Skin Care Products, One Skin Care Specialist Fights Back 2Health News:Clone Systems, Inc. Introduces On-Demand Penetration Testing Service 2Health News:Researchers show that nitric oxide-donating naproxen can boost colorectal cancer prevention 2
(Date:2/27/2015)... , Feb. 27, 2015  Pomerantz LLP is investigating ... ("Vitae" or the "Company") (NASDAQ: VTAE ).  ... Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. ... certain of its officers and/or directors have violated Sections ... 1934.  On February 27, 2015, the ...
(Date:2/27/2015)... 27, 2015 Securities lawyers at Dunnam ... Pharmaceuticals, Ltd. (NASDAQ: SLXP ) in connection ... SLXP investors are encouraged to contact attorney Hamilton Lindley ... investigation focuses upon the shareholder value of the transaction. ... receive only $158.00 per share in cash. At least ...
(Date:2/27/2015)... 2015 Report Details   ... trends, R&D progress, and predicted revenues ,Where is the ... the commercial prospects for this market and related technologies? ... other trends to 2025, discussing data, opportunities and prospects. ... regenerative medicine : cell-based therapies that aim to ...
Breaking Medicine Technology:SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vitae Pharmaceuticals, Inc. - VTAE 2Translational Regenerative Medicine: Market Prospects 2015-2025 2Translational Regenerative Medicine: Market Prospects 2015-2025 3Translational Regenerative Medicine: Market Prospects 2015-2025 4Translational Regenerative Medicine: Market Prospects 2015-2025 5Translational Regenerative Medicine: Market Prospects 2015-2025 6Translational Regenerative Medicine: Market Prospects 2015-2025 7Translational Regenerative Medicine: Market Prospects 2015-2025 8
... 12, 2007 - Immunicon,Corporation (NASDAQ-GM:IMMC) will exhibit ... at the Los Angeles,Convention Center, April 15 ... Services(SM), the new CellCapture(TM) CTC,Mouse/Rat Kit and ... Immunicon Pharma Services offers assay development and ...
... reduce the risk of cancer,returning after surgery for ... placebo in this trial will now be offered,Glivec ... of Glivec as,adjuvant therapy in GIST patients following ... approved as effective therapy for patients with,advanced metastatic ...
Cached Medicine Technology:Immunicon Will Exhibit CellCapture CTC Mouse/Rat Kit and EasyCount,System for Automated Cell Counting at AACR 2Immunicon Will Exhibit CellCapture CTC Mouse/Rat Kit and EasyCount,System for Automated Cell Counting at AACR 3Immunicon Will Exhibit CellCapture CTC Mouse/Rat Kit and EasyCount,System for Automated Cell Counting at AACR 4Positive Results Prompt US National Cancer Institute to Make Glivec,Available to Patients in Post-Surgical GIST Study 2Positive Results Prompt US National Cancer Institute to Make Glivec,Available to Patients in Post-Surgical GIST Study 3Positive Results Prompt US National Cancer Institute to Make Glivec,Available to Patients in Post-Surgical GIST Study 4Positive Results Prompt US National Cancer Institute to Make Glivec,Available to Patients in Post-Surgical GIST Study 5Positive Results Prompt US National Cancer Institute to Make Glivec,Available to Patients in Post-Surgical GIST Study 6
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: